Aytu Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Aytu Biopharma

28/09/2023 24:54

* Aytu Biopharma Inc  AYTU.OQ  reported a quarterly adjusted
loss
of 59 cents​​ per share for the quarter ended in June. The lone
analyst forecast for the quarter was for a loss of 95 cents per
share.
    * Revenue rose 12% to $30.73 million from a year ago;
analysts
expected $27.69 million. 
    * Aytu Biopharma Inc's reported EPS for the quarter was a
loss
of 59 cents​.
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aytu Biopharma Inc shares had risen by 3.1% this
quarter and
lost 56.3% so far this year.
    * The company reported a quarterly loss of $2.46 million.
    * Wall Street's median 12-month price target for Aytu
Biopharma
Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
September 27 at 11:54 p.m. UTC. ​All figures in US dollars
unless otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.95          -0.59          Beat
 Mar. 31 2023      -0.63          -1.93          Missed
 Dec. 31 2022      -1.60          -1.31          Beat
 Sep. 30 2022      -3.60          -1.20          Beat